In osteolytic lesions, which are common in breast, lung, and multiple myeloma, cancer cells promote the activity of bone-resorbing osteoclasts 3, whereas osteoblasts orchestrate the development of osteoclasts by secreting RANKL and osteoprotegerin (OPG) 4. This evidence concerns the gene TNFRSF11B and plasma cell myeloma.